Advertisement

Biologics in Wound Management

  • Andrea De Pascalis
  • Valentina Dini
Chapter
  • 23 Downloads

Abstract

Biologics are a new class of drugs which mimic the action of human proteins and interact with circulating proteins or cellular/extracellular targets, blocking their activities. The main application of biologics in dermatology concerns psoriasis, atopic dermatitis, and recently hidradenitis suppurativa, with a growing interest in chronic wound management. Inflammatory wounds such as pyoderma gangrenosum and vasculitic ulcers are the main indications for biologics, according to the pathogenesis of them. Wondering the use of this drugs we have to consider the possible contraindications, side effects, and the remarkable costs. Checking the literature we can find just case reports or small case series about their use in chronic wound therapy.

Keywords

Biologics Chronic wounds Skin ulcers Pyoderma gangrenosum Vasculitic ulcers 

Notes

Conflict of Interest

The authors declare no conflict of interest.

References

  1. 1.
    Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46(1):1–23.CrossRefPubMedGoogle Scholar
  2. 2.
    Marzano AV, Fanoni D, Antiga E, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178(1):48–56.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36(12):1681–90.CrossRefGoogle Scholar
  4. 4.
    Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645–60.CrossRefPubMedGoogle Scholar
  5. 5.
    Vena GA, Cassano N. Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics. 2007;1(2):93–103.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Mitoma H, Horiuchi T, Tsukamoto H, et al. Molecular mechanisms of action of anti- TNF-alpha agents—comparison among therapeutic TNF-alpha antagonists. Cytokine. 2018;101:56–63.CrossRefGoogle Scholar
  7. 7.
    Haridas V, Shetty P, Dsouza LC, et al. Pyoderma gangrenosum in Sjogren’s syndrome and its successful treatment with topical application of etanercept. Int J Rheum Dis. 2017;20(5):657–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Fleischmann R, Stern R, Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2004;4(8):1333–44.CrossRefPubMedGoogle Scholar
  9. 9.
    Tang C, Chen S, Qian H, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012;135(2):112–24.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lee WS, Choi YJ, Yoo WH. Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. J Eur Acad Dermatol Venereol. 2017;31(2):e75–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Manning CD, Burman M, Christensen SB, et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol. 1999;128(7):1393–8.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–55.CrossRefPubMedGoogle Scholar
  13. 13.
    Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Care Res. 2002;47:17–21.CrossRefGoogle Scholar
  14. 14.
    Ellerin T, Rubin RH, Weinblatt ME. Infections and anti- tumor necrosis factor alpha therapy. Arthritis Rheum. 2003;48:3013–22.CrossRefPubMedGoogle Scholar
  15. 15.
    Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035–50.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol. 2003;139:1425–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Levine D, Strober BE. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Semin Cutan Med Surg. 2010;29:28–34.CrossRefPubMedGoogle Scholar
  18. 18.
    Hrycaj P, Korczowska I, Lacki JK. Severe Parkinson’s disease in rheumatoid arthritis patient treated with ifx. Rheumatology (Oxford). 2003;42:702–3.CrossRefGoogle Scholar
  19. 19.
    Chung ES, Packer M, Lo KH, FaSanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of ifx, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133–40.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Khanna D, McMahon M, Furst DE. Safety of tumor necrosisfactor- alpha antagonists. Drug Saf. 2004;27:307–24.CrossRefPubMedGoogle Scholar
  21. 21.
    Choucair MM, Fivenson DP. Pyoderma gangrenosum: a review of the disease and treatment options. Wounds. 2001;13(3):119–22.Google Scholar
  22. 22.
    Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther. 2013;38(6):563–72.CrossRefPubMedGoogle Scholar
  23. 23.
    Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013;149(6):762–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Fatima McKenzie, Devin Cash, Angela Gupta, Laurel W. Cummings & Alex Ortega-Loayza. Biologic and small molecule medications in the management of pyoderma gangrenosum, J Dermatolog Treat. 2018Sep 7;Epub.Google Scholar
  26. 26.
    Dini V, Romanelli M, Bertone M, Talarico S, Bombardieri S, Barachini P. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody. Int J Low Extrem Wounds. 2007 Jun;6(2):108–13.CrossRefPubMedGoogle Scholar
  27. 27.
    Papi M, Papi C. Vasculitic ulcers. Int J Low Extrem Wounds. 2016 Mar;15(1):6–16.CrossRefPubMedGoogle Scholar
  28. 28.
    Ntatsaki E., Carruthers D., Chakravarty K., et al. BSR and BHPR guideline for the 316 management of adults with ANCA-associated vasculitis, rheumatology. Oxford. 2014;317.Google Scholar
  29. 29.
    Charles P., Bienvenu B., Bonnotte B., et al. Rituximab: recommendations of the 319 French Vasculitis Study Group (FVSG) for induction and maintenance treatments 320 of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides, 321 Presse Med. 2013;42(10):1317–1330.Google Scholar
  30. 30.
    Van der Bijl AE, Allaart CF, Van Vugt J, et al. Rheumatoid vasculitis treated with infliximab. J Rheumatol. 2005;32:1607–9.PubMedGoogle Scholar
  31. 31.
    Fujikawa K, Kawakami A, Hayashi T, et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol. 2010;20:86–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Lui NL, Thumboo J, Fong KY. A case of refractory vasculitic ulcers in a systemic lupus erythematosus patient responding to rituximab and hyperbaric oxygen therapy. Int J Rheum Dis. 2009;12:366–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833–8.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Bonilla-Abadía F, Echeverri AF, Izquierdo JH, Cañas F, Cañas CA. Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection. Case Rep Rheumatol. 2012;2012:923897.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Weinstein DA, Kirsner RS. Refractory ulcers: the role of tumor necro- sis factor-alpha. J Am Acad Dermatol. 2010;63:146–54.CrossRefPubMedGoogle Scholar
  36. 36.
    Fox JD, Baquerizo-Nole KL, Keegan BR, Macquhae F, Escandon J, Espinosa A, Perez C, Romanelli P, Kirsner RS. Adalimumab treatment leads to reduction of tissue tumor necrosis factor-alpha correlated with venous leg ulcer improvement: a pilot study. Int Wound J. 2016;13(5):963–6. Google Scholar
  37. 37.
    Streit M, Beleznay Z, Braathen LR. Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J. 2006 Sep;3(3):171–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Ehrlich MR. Vasculitic leg ulcers: a complication of collagen-vascular disorders. Ostomy Wound Manage. 1993;39:12–4.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Andrea De Pascalis
    • 1
  • Valentina Dini
    • 1
  1. 1.Department of DermatologyUniversity of PisaPisaItaly

Personalised recommendations